Evidence map›Paper›PMID 35469366›Full record

ArticleNeurochemical research2022

Elevation of EGR1/zif268, a Neural Activity Marker, in the Auditory Cortex of Patients with Schizophrenia and its Animal Model.

Yuriko Iwakura, Ryoka Kawahara-Miki, Satoshi Kida, Hidekazu Sotoyama, Ramil Gabdulkhaev, Hitoshi Takahashi, Yasuto Kunii, Mizuki Hino, Atsuko Nagaoka, Ryuta Izumi and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Yuriko IwakuraDepartment of Molecular Neurobiology, Brain Research Institute, Niigata University, Niigata, Japan. yuriko@bri.niigata-u.ac.jp.ORCID http://orcid.org/0000-0001-5379-8405
Ryoka Kawahara-MikiNODAI Genome Research Center, Tokyo University of Agriculture, Tokyo, Japan.
Satoshi KidaGraduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo, Japan.
Hidekazu SotoyamaDepartment of Molecular Neurobiology, Brain Research Institute, Niigata University, Niigata, Japan.
Ramil GabdulkhaevDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Hitoshi TakahashiDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Yasuto KuniiDepartment of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Mizuki HinoDepartment of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Atsuko NagaokaDepartment of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Ryuta IzumiDepartment of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Risa ShishidoDepartment of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Toshiyuki SomeyaDepartment of Psychiatry, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Hirooki YabeDepartment of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Akiyoshi KakitaDepartment of Pathology, Brain Research Institute, Niigata University, Niigata, Japan.
Hiroyuki NawaDepartment of Molecular Neurobiology, Brain Research Institute, Niigata University, Niigata, Japan.
Fukushima Medical University · JPNiigata University · JPTokyo University of Agriculture · JPWakayama Medical University · JP

Funding

Japan Agency for Medical Research and Development JP21dm0207074Japan Agency for Medical Research and Development JP21wm0425019Japan Society for the Promotion of Science 18H05429Japan Society for the Promotion of Science 19K08053Japan Society for the Promotion of Science 21K18242Japan Society for the Promotion of Science JP21H00180Wellcome Trust 201917
6 · The paper itself

Abstract

The family of epidermal growth factor (EGF) including neuregulin-1 are implicated in the neuropathology of schizophrenia. We established a rat model of schizophrenia by exposing perinatal rats to EGF and reported that the auditory pathophysiological traits of this model such as prepulse inhibition, auditory steady-state response, and mismatch negativity are relevant to those of schizophrenia. We assessed the activation status of the auditory cortex in this model, as well as that in patients with schizophrenia, by monitoring the three neural activity-induced proteins: EGR1 (zif268), c-fos, and Arc. Among the activity markers, protein levels of EGR1 were significantly higher at the adult stage in EGF model rats than those in control rats. The group difference was observed despite an EGF model rat and a control rat being housed together, ruling out the contribution of rat vocalization effects. These changes in EGR1 levels were seen to be specific to the auditory cortex of this model. The increase in EGR1 levels were detectable at the juvenile stage and continued until old ages but displayed a peak immediately after puberty, whereas c-fos and Arc levels were nearly indistinguishable between groups at all ages with an exception of Arc decrease at the juvenile stage. A similar increase in EGR1 levels was observed in the postmortem superior temporal cortex of patients with schizophrenia. The commonality of the EGR1 increase indicates that the EGR1 elevation in the auditory cortex might be one of the molecular signatures of this animal model and schizophrenia associating with hallucination.

Indexed as

Auditory CortexSchizophreniaAnimalsDisease Models, AnimalEarly Growth Response Protein 1Epidermal Growth FactorNerve Tissue ProteinsProto-Oncogene Proteins c-fosRatsEarly Growth Response Protein 1Egr1 protein, ratEpidermal Growth FactorNerve Tissue ProteinsProto-Oncogene Proteins c-fosAuditory cortexAuditory hallucinationEarly growth response 1Epidermal growth factorImmediate early geneSchizophrenia

Identifiers

PMID35469366
OpenAlexW4224439937

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.